JP:520A Stock Latest News
Company AnnouncementsJ-Pharma wins ¥1.5bn AMED grant to advance global Phase III cancer trial3d ago520A
Company AnnouncementsJ-Pharma Wins AMED Backing for Global Biliary Tract Cancer Trial4w ago520A
Company AnnouncementsJ-Pharma Signs Global Licensing Term Sheet for Neuro-Inflammation Drug JPH0341M ago520A
Company AnnouncementsJ-Pharma Finalizes Restricted Stock Issuance and Tweaks Option Exercise Prices2M ago520A
Company AnnouncementsJ-Pharma Posts Quarterly Loss and Confirms Full-Year Red-Ink Forecast After TSE Growth Listing2M ago520A
Company AnnouncementsJ-Pharma Launches Restricted Stock Compensation for Directors and Executives3M ago520ACompany AnnouncementsJ-Pharma Advances Global Oncology Pipeline With Lead Drug Nanvuranlat4M ago520A
Company AnnouncementsJ-Pharma to Restructure Capital Surplus to Eliminate Retained Earnings Deficit5M ago520A
Company AnnouncementsJ-Pharma to Introduce Restricted Stock Plan to Align Directors With Shareholders5M ago520A
Company AnnouncementsJ-Pharma Overhauls Board and Creates CBO Role to Drive Global Growth5M ago520A
Company AnnouncementsJ-Pharma Flags Risks and Uncertainty in FY2026 Earnings Presentation5M ago520A- Company AnnouncementsJ‑Pharma Advances Nanvuranlat Into Pivotal Biliary Tract Cancer Trial: What Investors Should Watch5M ago520A
Company AnnouncementsJ-Pharma Books Over JPY 1 Billion in AMED Grant Income for MS Drug R&D5M ago520ACompany AnnouncementsJ‑Pharma’s JPH034 Phase 1 Trial: Early Safety Data in Focus for Investors6M ago520A